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Abstract
Background: Combination therapies are now recommended to treat uncomplicated malaria. We used a longitudinal design
to assess the incidence of malaria and compare the efficacies of 3 combination regimens in Kampala, Uganda.
Methodology/Principal Findings: Children aged 1–10 years were enrolled from randomly selected households in 2004–05
and 2007, and were followed at least monthly through 2008. Insecticide-treated bednets (ITNs) were provided in 2006.
Children were randomized upon their first episode, and then treated for all episodes of uncomplicated malaria with
amodiaquine/sulfadoxine-pyrimethamine (AQ/SP), artesunate/amodiaquine (AS/AQ), or artemether/lumefantrine (AL). Risks
of parasitological failure were determined for each episode of uncomplicated malaria and clinical parameters were followed.
A total of 690 children experienced 1464 episodes of malaria. 96% of these episodes were uncomplicated malaria and
treated with study drugs; 94% were due to Plasmodium falciparum. The rank order of treatment efficacy was AL . AS/AQ .
AQ/SP. Failure rates increased over time for AQ/SP, but not the artemisinin-based regimens. Over the 4-year course of the
study the prevalence of asymptomatic parasitemia decreased from 11.8% to 1.4%, the incidence of malaria decreased from
1.55 to 0.32 per person year, and the prevalence of anemia (hemoglobin ,10 gm/dL) decreased from 5.9% to 1.0%. No
episodes of severe malaria (based on WHO criteria) and no deaths were seen.
Conclusions/Significance: With ready access to combination therapies and distribution of ITNs, responses were excellent
for artemisinin-containing regimens, severe malaria was not seen, and the incidence of malaria and prevalence of
parasitemia and anemia decreased steadily over time.
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Introduction
Malaria is one of the most important infectious diseases in the
world. The problem is greatest in sub-Saharan Africa, where
infection with Plasmodium falciparum, the most virulent human
malaria parasite, is responsible for hundreds of millions of illnesses
and about one million deaths each year [1]. Recent advances have
led to some optimism regarding the control of malaria, and there
have been documented decreases in malarial incidence in a
number of parts of Africa [2–6]. However, the problem remains
great, with little improvement in much of Africa, and improved
malaria control interventions are needed. One important
component of malaria control is the prompt administration of
highly effective therapies to those ill with malaria. With increasing
resistance to older therapies, current WHO recommendations call
for the treatment of uncomplicated malaria in Africa with
artemisinin-based combination therapy (ACT). Multiple studies
have shown excellent efficacy for the two widely advocated ACTs
for Africa, artesunate/amodiaquine (AS/AQ) and artemether/
lumefantrine (AL) [7–12]. In addition, the non-ACT combination
regimen amodiaquine/sulfadoxine-pyrimethamine has shown
good antimalarial efficacy in many [13–16], but not all [7,12]
trials in Africa, and is recommended by the WHO as an
alternative therapy for malaria when ACTs are unavailable.
The epidemiology of malaria varies greatly across Africa, with
large variations in transmission intensity and both seasonal and
year-round transmission in different areas. The greater the
transmission intensity, the more rapidly humans acquire the
partial immunity to malaria that allows older children and adults
to be relatively spared from malarial incidence and risks of severe
malaria. Thus, in high transmission areas children acquire
effective immunity over the first few years of life, and malarial
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illness is uncommon in older children and adults. In areas with
lower levels of transmission, including many cities, the acquisition
of immunity occurs more slowly. The level of immunity in a
population directly impacts upon responses to antimalarial
therapies, especially in the context of sub-optimal treatments, as
the immune response plays an important role in control of
infection, and there is a clear correlation between transmission
intensity, level of antimalarial immunity, and response to therapy
with partially effective agents [17–18].
We studied the comparative efficacy of 3 antimalarial
combination therapies in an urban cohort of children in Kampala,
a city with a level of malaria transmission that is relatively low for
sub-Saharan Africa. An interim analysis identified a clear rank-
order of treatment efficacy (AL . AS/AQ . AQ/SP) [12].
Malarial incidence was heterogeneous, and associated with host
genetics, use of bednets, and distance of a child’s residence from a
mosquito breeding site [19]. The efficacy of AQ/SP diminished
over time, but this change appeared to be due to changes in host
immunity rather than increasing parasite resistance to the
components of AQ/SP [20]. We now present a final evaluation
of the relative efficacies of the 3 combination antimalarial
therapies, changes in the prevalence of malarial parasitemia and
incidence of malaria over time, and other clinical features in this
urban cohort of Ugandan children.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Enrollment of cohort
A detailed description of the cohort has been published previously
[12]. The study was conducted in the Mulago III parish of Kampala,
where malaria is reportedly mesoendemic, occurring throughout the
year, with peaks during and after the two rainy seasons. A census was
carried out from July to October 2004, enumerating a population of
16,172 [21]. All children from randomly selected households were
screened for enrollment. Enrollment took place between November
2004 and April 2005 and again from January–May 2007 to enroll
younger children from study households who had reached an eligible
age. Eligibility criteria were: age 1 to 10 years, agreement to come to
the study clinic for any febrile episode or illness, agreement to avoid
medications administered outside the study, agreement to remain in
Kampala during the study period, no known adverse reactions to the
study medications, weight 10 kg or more, absence of severe
malnutrition or known serious chronic disease, absence of life
threatening screening laboratory results, and willingness of parent or
guardian to provide written informed consent. Children with
symptomatic malaria on the day of screening were treated with
quinine and enrolled only after documentation of a negative blood
smear 7 days after initiation of therapy. The study received ethical
approval from the Uganda National Council of Science and
Technology, the Makerere University Research and Ethics Com-
mittee, and the University of California, San Francisco Committee
on Human Research.
Follow-up of study participants
Parents and guardians were asked to bring their children to the
study clinic for all medical care. The clinic was open daily from 8
AM to 5 PM, and after-hours care was available. Participants who
presented with new medical problems underwent a standardized
evaluation. Malaria was diagnosed if a child had complicated
malaria (presence of severe malaria or danger signs [22]) or fever
(documented tympanic temperature 38.0uC or history of fever in
the previous 24 hours) and any parasitemia. Children underwent
routine clinical assessment at least monthly. Blood smears were
performed monthly until April 2006, and every 3 months
thereafter. Asymptomatic parasitemia was not treated. Medica-
tions with antimalarial activity were avoided for the treatment of
nonmalarial illnesses if possible.
Treatment allocation and study drug administration
Participants were randomly assigned to receive 1 of 3 oral
regimens at their first episode of uncomplicated malaria and then
for all subsequent episodes diagnosed during the study. Study
medications were administered by the nurses according to
modified WHO recommendations for weight-based administra-
tion of fractions of tablets. The regimens were: AQ/SP (AQ,
10 mg/kg on the first 2 days and 5 mg/kg on the third day;
sulfadoxine, 25 mg/kg and pyrimethamine, 1.25 mg/kg on the
first day); AS/AQ (AQ as above and artesunate, 4 mg/kg on all 3
days); and artemether 20 mg/lumefantrine 120 mg twice daily for
3 days (5 through 14 kg, 1 tablet; 15 through 24 kg, 2 tablets; and
25 through 34 kg, 3 tablets per dose). Administration of first daily
doses were directly observed by study nurses; second daily doses of
medication or placebo (for AQ/SP and AS/AQ arms) were given
to the parents or guardians to administer in the evening. All study
personnel involved in outcome assessment were blinded to
treatment allocation. Study participants and their caregivers were
not informed of their assigned treatment regimens. Placebos were
administered to match the twice-daily schedule of AL. However,
because the study drugs were not identical in appearance and
taste, the study was considered single-blind. After treatment in the
clinic, patients were observed for 30 minutes and the dose was
readministered if vomiting occurred. Patients who vomited
persistently were referred for treatment with parenteral quinine.
Participants with severe malaria or danger signs were also treated
with quinine. The AQ/SP treatment arm was discontinued in
March 2007 after our interim analysis demonstrated inferior
efficacy [12], and children in this arm were randomized to one of
the other two arms. The AS/AQ arm was discontinued in January
2008 due to loss of availability of the study formulation of AS, and
children in this arm were moved to the AL arm.
Follow-up and outcome classification
Participants diagnosed with malaria were asked to return on
days 1, 2, 3, 7, 14, and 28 or any other day they felt ill. Follow-up
evaluation consisted of a standardized medical history and physical
examination. Blood was obtained by finger prick for thick blood
smears and storage on filter paper on all follow-up days, except
day 1. Treatment outcomes were classified according to 2005
WHO guidelines; for this analysis all failures (early treatment
failure, late clinical failure, and late parasitological failure) were
combined. Patients with failure within 14 days of initiation of
therapy were treated with quinine (10 mg/kg three times a day for
7 days, unsupervised), beginning a new 28-day follow-up schedule.
Symptomatic malaria diagnosed more than 14 days after a
previous episode was managed according to the study protocol.
Safety outcomes have been reported previously [12,23].
Laboratory methods
Blood smears and molecular genotyping methods to distinguish
recrudescences from new infections were performed as previously
described [12]. When P. falciparum DNA was not identified by
genotyping in a sample with a positive blood smear, parasite
species was determined by amplification of 18S small subunit
ribosomal DNA, as previously described [24].
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Statistical analysis
The sample size for this study was calculated and outcomes
were analyzed as previously described [12]. Based on an interim
analysis, the data and safety monitoring board recommended that
the AQ/SP treatment arm be dropped in March, 2007. Efficacy
data were evaluated with an intention-to-treat analysis including
all patients with falciparum malaria who were randomized to
study drug therapy [12]. Risks of treatment failure were estimated
with the Kaplan-Meier product limit formula. Data were censored
for patients who did not complete follow-up or were reinfected
with non-falciparum species and for new infections according to
outcomes adjusted by genotyping. Changes in hemoglobin over
time were analyzed using generalized estimating equations to
account for repeated measures within individuals.
Results
Characteristics of study participants
The cohort included 690 children aged 1 to 10 years at
enrollment; 601 were enrolled from November 2004-April 2005,
and an additional 89 from January–May 2007 (figure 1). All
participants were from randomly selected households in the
Mulago III parish of Kampala [21]. The second period of
enrollment included only children from households already taking
part in the study, to include younger children who had reached an
eligible age since the initial period of enrollment. Characteristics of
study participants are shown in table 1. Of these, 209 children
were withdrawn before the end of study follow-up in December
2008 for the following reasons: movement out of study area
(n = 110), inability to locate participant after 60 consecutive days
(n = 61), withdrawal of informed consent (n = 22), inability to
comply with the study procedures (n = 3), serious adverse event
due to study medication (n = 1), and diagnosis of serious chronic
disease requiring frequent medical care (n = 12). The percentage of
participants lost to follow-up was similar during each year of the
study (7.8% to 9.5% per year), and it did not differ between
treatment arms. A total of 481 (69.7%) children completed the
study in December 2008. At enrollment bednet use was reported
in 43% of the cohort, but only 6% reported using an insecticide-
treated bednet (ITN) [21]. Between May and June 2006, ITNs
were distributed to all study participants.
Species of infecting parasites
As expected most episodes of malaria (94%) were caused by P.
falciparum. When P. falciparum was identified, we did not search for
other species, so mixed infections were not identified. However,
Figure 1. Trial profile.
doi:10.1371/journal.pone.0011759.g001
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the three other human malaria parasite species were all seen, with
disease caused solely by P. malariae in 66 episodes, P. ovale in 13
episodes, and P. vivax in 7 episodes.
Asymptomatic parasitemia and incidence of malaria
Asymptomatic parasitemia was common at study enrollment in
2004–05 (17%) [21]. The prevalence of asymptomatic parasitemia
decreased over the course of the study to only 1.4% in 2008
(table 1). A total of 1464 episodes of malaria, defined as
documented fever or history of fever with any parasitemia on
blood smear, occurred over the study period. Of the 690 children
enrolled in the study, 430 had at least one episode of malaria
(range 1–30 episodes), whereas 260 experienced no episodes.
The incidence of malaria was year-round, with large variation,
consistent with variable year-round rainfall and malaria transmis-
sion in Kampala (figure 2A). Incidence decreased steadily over the
4 full years of follow-up, from 1.02 episodes per person year in
2005 to 0.32 episodes per person year in 2008 (table 1). Malaria
incidence decreased with increasing age, with the highest
incidence in children aged 0 to 5 years (0.87 per person year)
and lowest in those 11 to 15 years (0.48 per person year).
However, age-related differences may be overstated in this
analysis, since older ages contributed more person time late in
the study, when incidence was lower. In any event, differences in
incidence among these age groups were less than in reports from
other areas of Africa with high transmission intensity [25],
consistent with the moderate level of malaria transmission in
Kampala. Changes in incidence over time were very similar for
younger and older children in the cohort (figure 2B). Malaria risk
was greater in children residing closer to a mosquito breeding site
[19], but differences based on place of residence decreased over
time, such that by the end of the study these differences were lost
(figure 2C). ITN use was associated with a reduction in the
incidence of malaria from 1.08 to 0.51 per person year. However,
ITN use did not fully explain the decreasing incidence of malaria,
as marked decreases were seen both before and after the
widespread initiation of ITN use in May–June 2006.
Treatment outcomes
Final data from our study offer an update over a prior report
[12]. Comparisons were over varied intervals, as the AQ/SP
treatment arm was discontinued in March 2007 after our interim
analysis demonstrated inferior efficacy and the AS/AQ arm was
discontinued in January 2008 due to loss of availability of the study
Table 1. Description of patient population and malaria incidence by year.
Variable Year
2004 2005 2006 2007 2008
Number of children observed 240 601 549 595 530
Female, n (%) 130 (54%) 287 (48%) 259 (47%) 291 (49%) 257 (48%)
Person years of observation 23 520 523 543 478
Median age in years (IQR) 6.0 (4.1–8.1) 6.5 (4.1–8.5) 7.5 (5.1–9.5) 7.9 (5.3–10.3) 8.9 (6.2–11.2)
ITN coverage1 7.2% 6.2% 64.7% 99.4% 100%
Episodes of malaria 36 530 451 294 153
New episodes of malaria 36 (100%) 499 (94.2%) 420 (93.1%) 276 (93.9%) 150 (98.0%)
Recrudescent episodes of malaria 0 31 (5.8%) 31 (6.9%) 18 (6.1%) 3 (2.0%)
Parasite species2
P. falciparum 35 (97.2%) 497 (93.8%) 431 (95.6%) 272 (92.5%) 142 (92.8%)
P. malariae 1 (2.8%) 25 (4.7%) 14 (3.1%) 18 (6.1%) 9 (5.9%)
P. ovale 0 6 (1.1%) 4 (0.9%) 2 (0.7%) 1 (0.7%)
P. vivax 0 2 (0.4%) 2 (0.4%) 2 (0.7%) 1 (0.7%)
Treatments for malaria
AQ+SP3 13 (36.1%) 179 (33.8%) 164 (36.4%) 40 (13.6%) 0
AS+AQ4 11 (30.6%) 164 (30.9%) 136 (30.2%) 105 (35.7%) 18 (11.8%)
AL 12 (33.3%) 153 (28.9%) 140 (31.0%) 142 (48.3%) 132 (86.3%)
Quinine 0 28 (5.3%) 10 (2.2%) 5 (2.0%) 3 (2.0%)
Quinine + Clindamycin 0 6 (1.1%) 1 (0.2%) 2 (0.7%) 0
Asymptomatic parasitemia 44/374 (11.8%) 401/5351 (7.5%) 97/3228 (3.0%) 52/1935 (2.7%) 24/1681 (1.4%)
Mean hemoglobin gm/dL (SD) 12.1 (1.3) 12.0 (1.3) 12.3 (1.2) 12.3 (1.1) 12.7 (1.1)
Hemoglobin ,10 gm/dL 18/306 (5.9%) 200/3002 (6.7%) 85/2687 (3.2%) 83/2666 (3.1%) 21/2057 (1.0%)
Incidence all episodes of malaria (95% CI)5 1.55 (1.09–2.14) 1.02 (0.94–1.11) 0.86 (0.79–0.95) 0.54 (0.48–0.61) 0.32 (0.27–0.38)
Incidence new episodes of malaria (95% CI)5 1.55 (1.09–2.14) 0.96 (0.88–1.05) 0.80 (0.73–0.88) 0.50 (0.45–0.57) 0.31 (0.27–0.37)
1percentage of days of observation with ITN coverage.
2considering only symptomatic infections.
3discontinued in March, 2007.
4discontinued in January, 2008.
5per person years of observation.
doi:10.1371/journal.pone.0011759.t001
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Figure 2. Incidence of malaria over time. Incidence of malaria in the full cohort (A), stratified for age (B), and stratified based on distance of
residence from a swamp (C) are shown. Smoothed lines were produced in R (version 2.9.0) using Friedman’s SuperSmoother and considering 1339
new episodes of malaria over 710,004 person-days of follow up. This analysis did not include the 89 children enrolled in 2007. Monthly rainfall data
are from the Uganda Department of Meteorology; measurements were at Makerere University, ,2 km from the Mulago III parish, where study
subjects resided.
doi:10.1371/journal.pone.0011759.g002
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formulation of AS. Of the 1464 episodes of malaria 1409 (96%)
were uncomplicated malaria treated using one of the 3 study
medications (table 1). In addition, 31 treatments with quinine were
given for complicated malaria, 12 for uncomplicated malaria after
failure of a study drug within 14 days, and 3 for potential adverse
events due to study drugs; 9 treatments with quinine plus
clindamycin were provided after failure of a course of quinine
within 14 days. Genotype-corrected failures at 28 days were
uncommon with the two ACT regimens, but significantly more
common with AQ/SP (figure 3) [12]. The failure rate with AQ/
SP, but not the ACT regimens, increased over time. In a prior
analysis this increase appeared to be due to decreasing immunity
in our cohort, rather than increasing resistance of parasites to AQ
and SP, as the prevalence of known resistance-mediating parasite
polymorphisms did not change, but decreases in markers of host
immunity were associated with increased risk of failure [20]. As
noted previously, parasite clearance was much more rapid with the
ACT regimens than with AQ/SP [12]. The proportion of subjects
that remained parasitemic 2 or 3 days after the initiation of
treatment did not increase over time for any treatment arm.
Overall, the efficacies of the ACT study regimens remained
excellent (less than 5% rates of genotype-corrected failure) through
the course of the study.
Anemia
Measures of anemia improved through the course of the study.
For the 4 full years of observation, the annual overall prevalence of
anemia, considering all measurements over the course of the year
and anemia defined as hemoglobin ,10 gm/dl, decreased from
6.7% in 2005 to 1.0% in 2008 (table 1). Both the increase in mean
hemoglobin (0.24 g/dL per year, p,0.001) and decrease in the
probability of having hemoglobin ,10 gm/dl (relative risk 0.54
per year, p,0.001) were statistically significant. Over the course of
the study only 7 of 10,718 hemoglobin measurements were
,7 gm/dL (minimum value 6.3 gm/dL).
Hospital admissions and severe disease
Remarkably, no cases of severe malaria [26] and no deaths
occurred during the 4-year duration of our study. A total of 73
hospital admissions occurred, of which 21 were due to malaria.
The majority of all admissions and of malaria-related admissions
occurred in the first year of the study. All cause hospital admissions
Figure 3. Drug efficacy over time. The annual 28-day risk of failure of treatment of uncomplicated falciparum malaria with the three study
regimens, both unadjusted (considering all recurrences) and adjusted by genotyping (considering only recrudescences) is shown. This analysis did
not include episodes of malaria that occurred in 2004. Error bars represent upper limits of the 95% confidence intervals.
doi:10.1371/journal.pone.0011759.g003
Urban Malaria Cohort in Uganda
PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11759
decreased from 40 in 2005 to 7 in 2008, and admissions due to
malaria decreased from 15 in 2005 to 1–3 per year in 2006–08.
The 21 malaria-related hospitalizations, all leading to treatment
with quinine, were for single seizures (15 subjects), hyperparasi-
temia (parasite density greater than 500,000/mL; 3 subjects),
inability to sit or stand (2 subjects), and persistent vomiting (1
subject). Therapy with quinine was required for 28 subjects in
2005 (including 14 treatments after a single convulsion, 5 for early
treatment failure, and 3 for hyperparasitemia); 10 subjects in 2006
(3 after a single convulsion and 3 for late clinical failure); 5 subjects
in 2007 (3 for a single convulsion); and 3 subjects in 2008 (all for a
single convulsion).
Discussion
We followed 690 children in Kampala, Uganda for up to 4
years and identified 1464 episodes of malaria. Our study design
included ready access to care for all medical problems. Thus,
treatment outside of our study protocol was very uncommon, and
we obtained accurate measures of malarial incidence and
antimalarial drug efficacy. Children were randomized to one of
3 combination regimens with the first episode of uncomplicated
malaria, and we subsequently followed them through up to 30
episodes of malaria. Although further comparisons were limited
due to the sequential drop-out of two treatment arms, our results
add to our interim analysis [12], showing a clear rank order in the
efficacy of our combination treatment arms. In addition, our study
offered important insights into the incidence of malaria in
Kampala in the context of high quality health care. With available
prompt therapy for each episode of malaria and adoption of ITNs,
study children experienced remarkable decreases in the prevalence
of malarial parasitemia and incidence of malaria over time, and no
episodes of severe malaria and no deaths were seen.
Additional efficacy comparisons beyond those previously report-
ed were limited by our need to eliminate the AQ/SP treatment arm
due to inferior efficacy in 2007 and the AS/AQ arm when the study
formulation of AS was no longer available in early 2008. Consistent
with earlier analyses, both ACTs demonstrated excellent efficacy,
but AL was superior to AS/AQ [12]. This result is not surprising, as
AQ resistance is fairly common in East Africa, and AS/AQ was also
inferior to AL in studies from Tanzania [7–8] and Republic of
Congo [10]. Our results and others suggest that, at least for East
Africa, AL is a more appropriate choice than AS/AQ for the
treatment of malaria.
We identified remarkable decreases in the incidence of malaria
and the prevalences of asymptomatic malarial parasitemia and
anemia over the course of our 4 year study. Undoubtedly, these
decreases were due to multiple factors. First, a decrease in malarial
incidence is expected with increasing age, although in this area of
relatively low malaria transmission, changes in incidence with age
were modest [19]. Second, we provided ITNs to all study
participants in mid-2006. Third, the highly efficacious ACT AL
became the standard therapy for uncomplicated malaria in
Uganda in 2006. Although AL distribution was limited in
Kampala, its use presumably contributed to decreased malaria
transmission. Indeed, due to malaria control measures including
ITNs and improved therapies, the incidence of malaria has been
documented to decrease in some other areas of Africa [2–6]. A
fourth factor contributing to the dramatic decrease in malarial
incidence in our cohort was likely the prompt provision of effective
therapy for each episode of malaria. With prompt effective
therapy, children were rapidly cured, recrudescences leading to
recurrent illness were uncommon, and progression to severe
malaria was eliminated. Although interpretations are complex due
to multiple changing factors, our results offer support for ready
availability of ACTs for the treatment of malaria as a critical
component of malaria control efforts.
The most ominous feature of falciparum malaria is progression to
severe malaria, with subsequent high mortality. It seems likely that
prompt evaluation of febrile illnesses and prompt therapy for all
illnesses diagnosed as malaria will decrease the incidence of severe
malaria. In our study 1464 episodes of malaria were seen, 21 were
complicated, mostly due to single seizures soon after presentation,
and no episodes of severe malaria and no deaths were seen. These
results further support emphasis on availability of prompt effective
therapy for those with malaria as a key control strategy.
It is useful to consider our results from a cohort of children in
Kampala in the context of current malaria control efforts across
Africa. Resources for malaria control have increased greatly in
recent years, and initial gains in control have been seen, with
marked decreases in malarial parasitemia and incidence in some
areas. At the same time, many areas of Africa continue to have
very high levels of malaria transmission and disease incidence. Our
results suggest that, in an area of intermediate transmission,
prompt therapy with effective agents greatly limits progression to
severe disease or death. Thus, distribution of new effective
therapies across Africa is a critical priority. Nonetheless, with
prompt and effective therapy the incidence of malaria, although
decreased, remained quite high in our cohort, and so additional
control measures, including ITNs, rational use of insecticides, and,
when available, an effective vaccine, are also needed for control of
malaria in Africa.
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